Chinese biopharmaceutical company acquires a small nucleic acid drug company for 1.2 billion yuan, with assets including a pipeline for reducing fat and protecting muscles.

After acquiring innovative pharmaceutical company Lixin Pharmaceuticals for $500 million in 2025, domestic pharmaceutical giant China Biopharmaceuticals announced another acquisition deal worth 1.2 billion RMB. On the evening of January 13, the Hong Kong-listed pharmaceutical leader China Biopharmaceuticals announced that it will acquire the small nucleic acid innovation pharmaceutical company Hegia Biotechnology for a total price of 1.2 billion RMB. China Biopharmaceuticals stated that this is the first major acquisition initiated by a large pharmaceutical company in the domestic small nucleic acid field.